vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.
Company profile
Ticker
AWH
Exchange
Website
CEO
Valerie Palmieri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, ABIOTIC SYSTEMS
SEC CIK
Corporate docs
Subsidiaries
IllumeSys Pacific, Inc........................................................ • Ciphergen Technologies, Inc.............................................. • ASPiRA Labs, Inc................................................................ • ASPiRA IVD, Inc................................................................ ...
IRS number
330595156
AWH stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
12 Apr 24
424B3
Prospectus supplement
11 Apr 24
S-1
IPO registration
5 Apr 24
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEF 14A
Definitive proxy
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
Transcripts
AWH
Earnings call transcript
2023 Q4
28 Mar 24
AWH
Earnings call transcript
2023 Q3
13 Nov 23
AWH
Earnings call transcript
2023 Q2
14 Aug 23
AWH
Earnings call transcript
2023 Q1
11 May 23
AWH
Earnings call transcript
2022 Q4
22 Mar 23
AWH
Earnings call transcript
2022 Q3
10 Nov 22
AWH
Earnings call transcript
2022 Q2
10 Aug 22
AWH
Earnings call transcript
2022 Q1
11 May 22
AWH
Earnings call transcript
2021 Q4
23 Mar 22
AWH
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
SC 13G/A
Schultz Eric Adam
8 Apr 24
3
Sandra Milligan
4 Apr 24
4
Nicole Sandford
20 Feb 24
4
Torsten Hombeck
14 Feb 24
4
Minh Hoang Merchant
14 Feb 24
4
Nicole Sandford
30 Jan 24
4/A
Celeste Rachelle Fralick
29 Dec 23
4/A
Veronica GH Jordan
27 Dec 23
SC 13G
Schultz Eric Adam
26 Dec 23
3
ROBERT H DRYSDALE
8 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm |
Cash burn (monthly) | (no burn) | 1.29 mm | 1.37 mm | 1.61 mm | (no burn) | 503.67 k |
Cash used (since last report) | n/a | 8.54 mm | 9.10 mm | 10.67 mm | n/a | 3.34 mm |
Cash remaining | n/a | -3.18 mm | -3.75 mm | -5.31 mm | n/a | 2.01 mm |
Runway (months of cash) | n/a | -2.5 | -2.7 | -3.3 | n/a | 4.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 9 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 3.38 bn |
Total shares | 35.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schuler Tino Hans | 8.57 mm | $31.80 mm |
Schuler Henri George | 6.75 mm | $58.92 mm |
Sharman Tanya Schuler | 5.94 mm | $12.19 mm |
Seamark Capital | 5.67 mm | $0.00 |
Larry N Feinberg | 5.55 mm | $13.48 mm |
Schuler Jack W | 1.88 mm | $4.62 mm |
Vanguard | 182.85 k | $980.05 mm |
National Asset Management | 125.37 k | $672.01 mm |
BLK Blackrock | 63.17 k | $338.59 mm |
Geode Capital Management | 51.76 k | $277.51 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Nicole Sandford | Employee stock option Common Stock | Grant | Acquire A | No | No | 4.73 | 30,000 | 141.90 k | 30,000 |
14 Feb 24 | Torsten Hombeck | Employee stock option Common stock | Grant | Acquire A | No | No | 4.87 | 20,000 | 97.40 k | 20,000 |
14 Feb 24 | Minh Hoang Merchant | Employee stock option Common Stock | Grant | Acquire A | No | No | 4.87 | 11,000 | 53.57 k | 11,000 |
6 Dec 23 | Nicole Sandford | Common Stock | Buy | Acquire P | No | No | 3.36 | 5,000 | 16.80 k | 58,703 |
News
Cantor Fitzgerald Reiterates Neutral on Aspira Womens Health, Maintains $3.3 Price Target
10 Apr 24
Aspira Womens Health Q4 EPS $(0.30) Beats $(0.45) Estimate, Sales $2.13M Miss $2.54M Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
A Preview Of Aspira Womens Health's Earnings
27 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Press releases
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
22 Feb 24
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
25 Jan 24